RE:RE:Sanofi's M&A plans of insulin company hit by FTC delayWith Pfizer's US$43 Billion acquisition plans of Seagen in the hands of the Federal Trade Commission, who are experiencing capacity issues and increasing review delays, Pfizer's original plans to complete their acquisition of Seagen by Q4 2023 or Q1 2024, may in fact now be delayed until Q2/Q3 2024.
As Pfizer begins to process the general delays the FTC is experiencing, since the FTC's capacity will impact the review of Pfizer's take-over of Seagen, Pfizer will likely be seeking to reconfigure and move-up other business development activities and timelines by accelerating other M&A announcements, such as the potential acquisition of ONCY pelareorep, which is a strategic fit for the company as a "Bolt-On" acquisition, as Seagen acquisition is considered.